Effect of Bromocriptin in treatment of patients with polycystic ovaries.

Effect of Bromocriptin on insulin resistance in comparison with placebo in patients with polycystic ovaries referring to Golestan Hospital of Ahvaz.

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT2013030412699N1

Enrollment

Registered

2014-01-24

Start date

2013-02-07

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Polycystic Ovary Syndrome. Stein Leventhal Syndrome

Interventions

Intervention 1: Intervention Group: Bromocriptin with trade name cyclocet, made by Iran Hormone-Tehran company, gives once daily per oral for 8 days. Intervention 2: Control Group: Placebo as 2.5 mill

Treatment - Drugs

Placebo

Intervention Group: Bromocriptin with trade name cyclocet, made by Iran Hormone-Tehran company, gives once daily per oral for 8 days.

Control Group: Placebo as 2.5 milligram tablet, once daily per oral for 8 days. Placebo is made from micro-crystalline cellulose, lactose, starch,sorbitol and magnesium stearate which made in pharmac

Eligibility

Sex/Gender

Female

Age

16 Years to 45 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Patients with polycystic ovaries between 16 and 45 years old and Body Mass Index (BMI) more than 25. Exclusion criteria: Fasting blood sugar more than 126, hypothyroidism, prolactinoma, nonclassic congenital adrenal hyperplasia, psychosis, breast feeding, syncope attack, severe nausea and vomiting.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Blood Sugar. Timepoint: Before intervention and 8 days after intervention. Method of measurement: mg /dl with Glucose Oxidase method.;Fasting Insulin. Timepoint: Before intervention and 8 days after intervention. Method of measurement: micIU/ml, with chemiluminescence method.	—

Secondary

Measure	Time frame
Dizziness. Timepoint: Before intervention and daily during intervention. Method of measurement: Asking from patients.;Nausea and vomiting. Timepoint: Before intervention and daily during intervention. Method of measurement: Asking from patients.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactHomeira Rashidi

Ahvaz Jondishapour University of Medical Sciences

Golestanhospital@ajums.ac.ir+98 61 1374 3013

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026